


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**“LENVATINIB MESILATE CAPSULE” OBTAINS DRUG REGISTRATION
CERTIFICATE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “**Lenvatinib Mesilate Capsule**” (Brand name: Fukait (福凱特)), a liver cancer treatment drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. This product was filed as a Chemicals Category 4 drug, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has obtained approval for drug registration in China. The approved indication is: for the treatment of unresectable hepatocellular carcinoma patients who have not received systemic treatment in the past.

Lenvatinib is a multiple tyrosine kinase receptors (RTK) inhibitor, which can inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4), and also inhibit fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor KIT and RET fusion genes, thereby inhibiting tumor angiogenesis and tumor progression. Lenvatinib mesilate was the only drug that had obtained positive results in phase III clinical studies in the field of first-line targeted therapy for liver cancer in the past decade. Clinical data showed that the efficacy of lenvatinib mesilate was particularly impressive in the Chinese patient subgroup compared to the total global population. Lenvatinib mesilate has been adopted as the first-line drug for the treatment of middle-late stage liver cancer in countries including China, Japan, and the United States.

According to statistics, there are 466,000 new liver cancer patients in China each year, accounting for more than half of the global incidence (cited from: Cancer Statistics in China, 2015). Currently, only the brand-name drug of lenvatinib mesilate capsule is available in the domestic market, so there is a wide market potential. The approval for the launch of lenvatinib mesilate capsule developed by the Group will further improve the Group's anti-tumor product line layout and help reduce the economic burden of liver cancer patients in China.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 26 July 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.